Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial-Reference-Cited by-同舟云学术

Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial

Published:2021-04-08 Issue:13 Volume:27 Page:3567-3575
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Li Dapeng,Chi Yihebali,Chen Xiaohong,Ge Minghua,Zhang Yuan,Guo Zhuming,Wang Jun,Chen Jie,Zhang Jiewu,Cheng Ying,Li Zhendong,Liu Hui,Qin Jianwu,Zhu Jingqiang,Cheng Ruochuan,Xu Zhengang,Zheng Xiangqian,Tang Pingzhang,Gao Ming

Funder

Chia Tai TianQing Pharmaceutical Group Co., Ltd.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Survival in medullary thyroid carcinoma patients who fail to achieve a biochemical cure: implications of postoperative 1-month calcitonin levels and targeted therapy;World Journal of Surgical Oncology;2024-09-12

2. Therapeutic advances of targeting receptor tyrosine kinases in cancer;Signal Transduction and Targeted Therapy;2024-08-14

3. Combination of Sintilimab and Anlotinib for Metastatic Osteosarcoma: A Case Report;OncoTargets and Therapy;2024-08

4. Improved survival after primary tumor resection in distant metastasis medullary thyroid carcinoma: a population-based cohort study with propensity score matching;Scientific Reports;2024-07-27

5. Efficacy and Safety of Multikinase Inhibitors for Patients With Refractory Thyroid Cancer: Systematic Review and Network Meta-Analysis;The Journal of Clinical Endocrinology & Metabolism;2024-07-06